1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,290 | 4,520 | 03.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Alvotech Enters Supply, Commercialization Deal With Sandoz Covering Biosimilar Candidates | 7 | RTTNews | ||
| ALVOTECH Aktie jetzt für 0€ handeln | |||||
| Mo | Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates | 104 | GlobeNewswire (Europe) | REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| Do | Alvotech - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| Do | Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar | 53 | Seeking Alpha | ||
| Do | Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg | 198 | GlobeNewswire (Europe) | REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| 06.01. | Alvotech: Transactions of Managers and Closely Associated Persons | 17 | GlobeNewswire (USA) | ||
| 06.01. | Alvotech announces CEO transition | 10 | Seeking Alpha | ||
| 06.01. | Alvotech Appoints Lisa Graver As CEO, Rbert Wessman To Continue As Executive Chairman | 3 | RTTNews | ||
| 06.01. | Alvotech names Lisa Graver as new CEO as founder steps back | 4 | Investing.com | ||
| 06.01. | Alvotech announces planned CEO succession and leadership transition | 379 | GlobeNewswire (Europe) | R- bert Wessman to continue serving as Executive Chairman in full-time capacityLisa Graver appointed Chief Executive Officer REYKJAVIK, ICELAND (January 6, 2026) - Alvotech (NASDAQ: ALVO), a global... ► Artikel lesen | |
| 06.01. | Alvotech Secures $100 Million Term Loan Facility Led By GoldenTree | 12 | pulse2.com | ||
| 02.01. | Alvotech - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 31.12.25 | Alvotech Secures Term Loan Facility of USD 100 Million | 6 | GlobeNewswire (USA) | ||
| 29.12.25 | Alvotech: Changes in company's own shares | 13 | GlobeNewswire (USA) | ||
| 23.12.25 | Alvotech - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.12.25 | Alvotech's Financial Calendar for 2026 | 17 | GlobeNewswire (USA) | ||
| 22.12.25 | Alvotech announces European launch of biosimilar to Simponi | 14 | Seeking Alpha | ||
| 22.12.25 | Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma | 402 | GlobeNewswire (Europe) | Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, ICELAND (December 22, 2025) - Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the... ► Artikel lesen | |
| 19.12.25 | Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement | 19 | FiercePharma | ||
| 19.12.25 | Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. | 16 | Seeking Alpha |
1 2 3 4 5 Weiter >>
120 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 91,60 | +0,11 % | BioNTech-Aktie: Hält das starke Momentum? | Die BioNTech-Aktie meldet sich 2026 eindrucksvoll zurück. Seit Jahresbeginn liegt der Titel um rund 23% im Plus, notiert bei knapp 120 US$ und zählt damit zu den auffälligen Gewinnern an der Börse.... ► Artikel lesen | |
| BB BIOTECH | 51,90 | +0,97 % | BB Biotech: Gewinnsprung 2025 und höhere Dividende geplant | Die BB Biotech AG hat für das Geschäftsjahr 2025 vorläufig einen Nettogewinn von 578 Millionen CHF ausgewiesen, nach 76 Millionen CHF im Vorjahr. Die Ergebnisse der Biotech-Beteiligungsgesellschaft... ► Artikel lesen | |
| PAION | 0,100 | -14,89 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WIRD GEPRUEFT | Fuer folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wird ein Mistrade-Antrag geprueft:ISIN Datum Zeit Volumen Preis Fair Value (AS)DE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 3,892 | -0,87 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| EPIGENOMICS | 1,200 | +37,93 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| BIOFRONTERA | 2,360 | 0,00 % | BIOFRONTERA AG - Stabilität als strategisches Signal | ||
| HEIDELBERG PHARMA | 2,910 | +1,75 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Meilensteinzahlung des Partners Takeda | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Meilensteinzahlung des Partners Takeda
29.01.2026 / 13:27 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,800 | -0,45 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 17,000 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| BIOXXMED | 1,328 | -10,87 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,440 | +0,70 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,275 | +0,08 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| INFLARX | 0,738 | -1,40 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| NOVONESIS | 50,68 | -0,35 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen |
ALVOTECH gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALVOTECH finden Sie auf Wallstreet Online.